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A B S T R A C T
Recently, we found cardioprotective effects of ischemic preconditioning (IPC), and from a blocker of KCNQ
voltage-gated K+ channels (KV7), XE991 (10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone), in isolated rat
hearts. The purpose of the present study was to investigate the cardiovascular effects of IPC and XE991 and
whether they are cardioprotective in intact rats. In conscious rats, we measured the effect of the KV7 channel
blocker XE991 on heart rate and blood pressure by use of telemetry. In anesthetized rats, cardiac ischemia was
induced by occluding the left coronary artery, and the animals received IPC (2 × 5 min of occlusion), XE991, or
a combination. After a 2 h reperfusion period, the hearts were excised, and the area at risk and infarct size were
determined. In both anesthetized and conscious rats, XE991 increased blood pressure, and the highest dose
(7.5 mg/kg) of XE991 also increased heart rate, and 44% of conscious rats died. XE991 induced marked changes
in the electrocardiogram (e.g., increased PR interval and prolonged QTC interval) without changing cardiac
action potentials. The infarct size to area at risk ratio was reduced from 53 ± 2% (n = 8) in the vehicle
compared to 36 ± 3% in the IPC group (P < 0.05, n = 9). XE991 (0.75 mg/kg) treatment alone or on top of
IPC failed to reduce myocardial infarct size. Similar to the effect in isolated hearts, locally applied IPC was
cardioprotective in intact animals exposed to ischemia-reperfusion. Systemic administration of XE991 failed to
protect the heart against ischemia-reperfusion injury suggesting effects on the autonomic nervous system
counteracting the cardioprotection in intact animals.
1. Introduction
Treatment of acute myocardial infarction (AMI) aims to remove the
occlusion in the affected coronary artery and thereby re-establish blood
flow. Although reperfusion is essential, it can itself damage the myo-
cardium - a phenomenon known as reperfusion injury (Yellon and
Hausenloy, 2007). Ischemic preconditioning (IPC), which consists of a
series of short ischemic episodes to a target tissue, protects the heart
against ischemic-reperfusion injury (Murry et al., 1986; Piot et al.,
1997; Li et al., 1992). In animal studies, the ability of conditioning to
protect the heart is convincing, however in the clinical setting, results
are not as conclusive (Davies et al., 2013; Hausenloy et al., 2015; Walsh
et al., 2016; Botker et al., 2010).
Activation of large-conductance Ca2+ activated K+ channels
protects against ischemia-reperfusion injury, and inhibition of mi-
tochondrial ATP-sensitive K channels (KATP) channels partially abol-
ishes ischemic preconditioning (IPC) induced cardioprotection (Fryer
et al., 2000; Bentzen et al., 2009). The role of voltage-gated K+ chan-
nels type 7 (KV7) in the heart is not well established (Hedegaard et al.,
2016; Testai et al., 2016). The KV7 subtypes (KV7.1–7.5) are expressed
in rat and porcine left and right ventricles, coronary arteries and brain
tissue, as well as in the human heart (Hedegaard et al., 2014, 2016;
Khanamiri et al., 2013; Tinel et al., 1998; Ng et al., 2011). The KV7
channels contribute to the resting membrane potential in vascular
smooth muscle cells (Mackie and Byron, 2008). Blockade of Kv7
channels increases vascular tone in rodent blood vessels (Yeung et al.,
2007; Yeung and Greenwood, 2005; Mackie et al., 2008), and prevents
apoptosis in rat sympathetic neurons, suggesting a cytoprotective effect
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(Xia et al., 2002). A putative opener of KV7 channels, retigabine, was
reported to protect isolated rat hearts against ischemia-reperfusion in-
jury, and this was antagonized by a blockade of KV7 channels (Testai
et al., 2016). However, a high concentration of retigabine was used,
which may also block myocardial voltage-gated K+ channels
(Rundfeldt, 1997). We found that the pan-KV7 channel blockers XE991
and linopirdine (Wang et al., 1998, 2000; Jensen et al., 2005), reduce
infarct size in isolated rat hearts and post-hypoxia-reoxygenation cell
death in the HL cardiomyocyte cell line approximately 30% (Hedegaard
et al., 2016). Moreover, an additive protective effect was observed by
combining KV7 inhibition and IPC treatment. Furthermore, an opener of
KV7-channels abrogates the cardio-protective effects of IPC (Hedegaard
et al., 2016). However, it is unclear whether systemic administration of
KV7 channel blockers exerts cardioprotective effects in intact animals.
We hypothesized that administration of a KV7 channel blocker
would reduce ischemia-reperfusion injury in intact animals. To choose
the dose, we examined the effect of XE991 administration on heart rate,
blood pressure, and electrocardiogram (ECG) in intact animals. To in-
vestigate the effect of IPC and the KV7 channel blocker XE991 in an in
vivo rat model of AMI, we experimentally induced myocardial infarc-
tion in rats by ligating the left anterior descending coronary artery
(LAD), followed by evaluation of myocardial infarct size.
2. Material and methods
2.1. Animals
The animals were handled in accordance with national and in-
stitutional guidelines for animal research and the experimental work
approved by the Danish Animal Experiments Expectorate (license no.
2016-15-0201-00948 and 2016-15-0201-00982). Male Wistar rats
(Janvier, France) were used at 7–8 weeks of age in the AMI study, and
11–12 weeks of age in both the telemetry and myograph study. The rats
were housed in the animal facility in cages (Universal Euro III type
long) with standard wood bedding, received standard diet and had
access to water ad libitum, and were kept under temperature and hu-
midity-controlled conditions with 12 h/12 h light/dark cycles, respec-
tively.
2.2. Materials
Isoprenaline HCl, phenylephrine HCl, U4661 (9[(5Z)-7-
[(1R,4S,5S,6R)-6-[(1E,3S)-3- hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]
hept-5-yl]-5-heptenoic acid]), prazosin HCl, yohimbine, XE991 [10,10-
bis(4-pyridinylmethyl)-9(10H)-anthracenone], Evans blue 1%, 2,3,5-
Triphenyltetrazolium chloride (TTC) 1%, formaldehyde 4% buffered,
dimethylsulphoxide (DMSO) ≥ 99%, Dulbecco's Phosphate buffered
saline, (D8537) (All from Sigma-Aldrich, St. Louis USA).
2.3. Telemetric measurements of mean arterial blood pressure (MAP) and
heart rate
To examine hemodynamic changes after administration of XE991 in
conscious rats, we measured blood pressure and heart rate continuously
using radiotelemetry as previously described (Laursen et al., 2017). The
rats were anesthetized by a combination of ketamine (3 mg/kg; Keta-
minol®vet, Intervet International, AN Boxmeer, Netherlands) and xy-
lazine (0.75 mg/kg; Narcoxyl®vet, Intervet International, AN Boxmeer,
Netherlands), and a telemetric transducer (TA11PA-C40; Data Sciences
International, ST. Paul, MN, USA) was implanted. The abdominal skin
of the anesthetized rat was shaved and sterilized, and a midline incision
was made through the skin and abdominal wall. Surrounding intestines
were retracted with saline moistened gauze to access the abdominal
aorta. The aorta was separated from the caval vein, and a piece of 4-0
suture was placed underneath to occlude blood flow temporarily. Using
a bend 22-gauge syringe needle, the catheter of the telemetric
transducer was advanced into the aorta. A small amount of tissue ad-
hesive (3M Vetbond, 3M Animal Care Product, St. Paul, MN, USA) was
applied to anchor the catheter in place with a small fiber patch. The
aorta occlusion and the gauze sponge retraction were removed. The
transmitter was placed on top of the intestine. The abdominal wall and
skin were closed by 4-0 suture, and analgesia (subcutaneously 0.2 mg/
kg; Temgesic, Reckitt Benckiser Healthcare Limited, Hull, UK) was in-
jected.
The rats were allowed to recover for at least one week before the
experimental protocol was started. Telemetry signals were recorded
continuously for 2 h, before a consequent administration of three doses
of XE991 (0.075 mg/kg, 0.75 mg/kg and 7.5 mg/kg, intraperitoneally)
with an interval of 2 h between each administration, allowing clearance
of more than 90% of XE991 between each dosage assuming a half-life of
0.6 h as for the structurally similar compound linopirdine (Rakestraw
et al., 1994). After each intraperitoneal injection, the rats were allowed
to rest 10 min before we started the measuring to avoid stress affecting
the results. Moreover, we have compared active drug to the vehicle-
injected animals to examine the effect with XE991 as the only variable.
Registration and analyses were performed with Dataquest A.R.T soft-
ware 4.3 (Data Sciences International, St. Paul, MN, USA).
2.4. Myograph experiments
Rats were killed by a blow to the head, followed by exsanguination.
The mesenteric bed was removed, and it was immediately placed in
cold physiological salt solution (4 °C) of the following composition
(mM): NaCl 119, KCl 4.7, KH2PO4 1.18, MgSO4 1.17, NaHCO3 25, CaCl2
1.6, EDTA 0.026 and glucose 5.5. To elucidate the effect of XE991 on
vascular tone in resistance arteries, rat mesenteric small artery seg-
ments were isolated and mounted in microvascular myographs (Danish
Myotechnology, Aarhus, Denmark) for isometric tension recordings as
previously described (Bangshaab et al., 2019). The vessels were equi-
librated in oxygenated (5% CO2 in air) physiological salt solution (pH
7.4) heated to 37 °C. To determine the lumen diameter that the artery
would have had in vivo when relaxed and under a transmural pressure
of 100 mmHg, the vessels were stretch following a standardized pro-
cedure. Arteries were set to 90% of this diameter, which is the optimal
vessel circumference for maximal force development (Mulvany and
Halpern, 1977). To test tissue viability, arterial segments were sub-
jected to an isotonic physiological salt solution containing a high con-
centration of potassium (123 mM) or noradrenaline (10−5 M), resulting
in maximal contraction of the vessels. To test endothelial function, the
vessels were contracted with phenylephrine or noradrenaline and then
stimulated with acetylcholine (10 μM). To examine whether XE991
induced contraction, cumulative concentration-response curves for
XE991 were performed at resting tension or in vessels contracted to
20% of the maximum response by addition of 10−6 M phenylephrine.
To examine whether XE991 inhibited relaxation, concentration-re-
sponse curves for the β-adrenoceptor agonist, isoprenaline were ob-
tained in arteries contracted with the thromboxane analog, U46619
(10−7 M), in the absence and presence of XE991 (10−5 M). To avoid
contribution from α-adrenoceptors to the isoprenaline responses, the
curves were performed in the presence of prazosin (10−6 M) and yo-
himbine (10−6 M).
2.5. Electrocardiographic (ECG) measurements
KV7 channels are expressed in the conduction system and heart
muscle fibers (Testai et al., 2016; Hedegaard et al., 2016; Sanguinetti
et al., 1996). Therefore, in anesthetized animals, we examined the ef-
fect of XE991 compared to a vehicle on the electrical activity of the
heart. Rats were anesthetized with S-ketamine hydrochloride (60 mg/
kg; Pfizer, Ballerup Denmark) and xylazine (10 mg/kg; Rompun vet,
KVP Pharma + Veterinär produkte Bayer, Kiel Germany) mixture in-
traperitoneally. ECG was recorded for at least 30 min to ensure normal
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rhythm; following this, increasing doses of vehicle or XE991 were ad-
ministered with 30 min intervals in two subgroups of animals. Data
were obtained by the use of an animal bio-amplifier (AD Instruments
Oxford, United Kingdom), and the software automatically obtained the
different ECG values, as previously described (Comerma-Steffensen
et al., 2017)., The ECG signals were low-pass filtered by using a stan-
dard filter for rats. The rate-corrected QT interval (QTc) was calculated
using the standard Bazett's formula (QTC = QT/√RR).
2.6. Action potential recordings in ventricular preparations
To clarify whether there was a direct effect of XE991 on rat ven-
tricular myocytes, we recorded action potentials as previously de-
scribed (Abramochkin et al., 2018). Rats were anesthetized with in-
traperitoneal injection of 80 mg/kg ketamine and 10 mg/kg xylazine.
Heparin (1000 U/kg) was added to the anesthetic solutions to prevent
blood coagulation in the coronary vessels of the excised heart. The chest
was opened and the heart was rapidly excised and rinsed with Tyrode
solution of the following composition (in mM): NaCl 118.0, KCl 2.7,
NaH2PO4 2.2, MgCl2 1.2, CaCl2 1.2, NaHCO3 25.0, glucose 11.0, bub-
bled with carbogen gas (95% O2 + 5% CO2), pH 7.4. The preparations
of right atrium (including the intercaval region) were isolated and
pinned with the endocardial side up to the bottom of an experimental
chamber (3 ml) perfused with Tyrode solution (10 ml/min, 37.5 °C).
Since the right atrial preparations contained the sinoatrial node, they
were beating spontaneously throughout the experiment.
After 1 h of equilibration in the perfusion chamber, transmembrane
potentials were recorded from the endocardial surface of preparations
with sharp glass microelectrodes (30–45 MΩ) filled with 3M KCl con-
nected to a high input impedance amplifier Model 1600 (A-M Systems,
Sequim, WA, USA). The signal was digitized and analyzed using specific
software (L-card, Russia; DI-Soft, Russia; Synaptosoft, USA). Stable
impalements were maintained during the entire period of XE991
(10−5 M) application. Changes in spontaneous beating rate and action
potential duration at 50 and 90% of repolarization (APD90) were de-
termined.
2.7. The rat myocardial infarct model
The rats were anesthetized with S-ketamine hydrochloride (60 mg/
kg; Pfizer, Ballerup Denmark) and xylazine (10 mg/kg; Rompun vet,
KVP Pharma + Veterinär produkte Bayer, Kiel Germany) mixture in-
traperitoneally. One-third of these doses were applied approximately
every 45 min to attain a constant level of anesthesia. After shaving, the
rats were intubated and mechanically ventilated (80 breaths per min,
tidal volume at 2 ml per 100 g body weight, and 6 cmH2O positive end-
expiratory pressure). The rats were placed on a temperature-controlled
heating pad to maintain body temperature, and a pulse oximeter
(LifeVet, Eickemeyer, Vojens, Denmark) was connected to the animals.
MAP and heart rate were measured continuously through a heparin-
filled catheter placed in the left carotid artery through a midline inci-
sion on the neck and connected to a pressure transducer
(ADInstruments MLT0699, Oxford, United Kingdom). The signal was
recorded using Powerlab and LabChart (ADInstruments ML866 and
ML118, Oxford, United Kingdom).
The rats were randomly assigned to four groups subjected to dif-
ferent protocols: vehicle, IPC, XE991, and one receiving both IPC and
XE991. To access the heart, a thoracotomy in the third intercostal space
was performed, and the 4th and 5th ribs were cut through. The thymus
gland was moved aside, and the pericardium opened. Using a micro-
scope (Nikon SMZ645, Amsterdam, Netherlands), the LAD was ligated
using 6.0 silk suture with a taper point needle. The suture was threaded
through a pearl and a small plastic tube to create a reversible snare, and
the LAD was occluded according to the assigned group as illustrated in
Fig. 1. Successful ligation was confirmed by blanching of myocardial
tissue. Ischemia was induced by tightening the snare for 40 min. After
the ischemic insult, the snare was loosened, and the artery was re-
perfused for 2 h. IPC was achieved via two 5 min cycles of LAD oc-
clusion, each followed by 5 min of reperfusion. XE991 (0.75 mg/kg)
dissolved in DMSO (0.2 ml/kg of 3.765 mg XE991/ml DMSO), was
injected intraperitoneally 25 min before the main ischemic insult. The
dosage of XE991 administered in our study was based on the con-
centrations previously used in isolated rat hearts (Hedegaard et al.,
2016), and on an assumption of a volume of distribution of 2.0 L/kg as
for the structurally similar compound linopirdine (Rakestraw et al.,
1994). This resulted in an estimated dose of 0.75 mg/kg XE991 that is
equivalent to 1 μM plasma concentration. The reason for selecting
0.75 mg/kg XE991 was also based on our telemetric studies depicting
the effect of different doses of XE991 on MAP, and showing that the
high dose of XE991 resulted in death in 44% of the animals (see results
section 3.1). Animals that did not receive XE991 got an intraperitoneal
injection with a corresponding amount of DMSO.
2.8. Assessment of infarct size
At the end of the 2 h reperfusion period, the LAD was re-occluded,
and 1 ml of 1% Evans blue in phosphate-buffered saline was injected
into the left ventricle of the beating heart, circulating the accessible
vasculature, thereby leaving the area at risk (AAR) unstained (modified
from (Fiedler et al., 1982; Ovize et al., 1994). After 2 min with perfu-
sion of Evans blue, the heart was excised and frozen at −80 °C over-
night. Next day, the heart was sliced transversely into five sections,
which were gently rinsed with phosphate-buffered saline. To distin-
guish vital tissue from infarcted areas, the slices were submerged in a
1% TTC solution in phosphate-buffered saline at 37 °C for 3 min, im-
mersed in cold water, and stored in 4% formaldehyde overnight. Infarct
size and AAR were assessed using ImageJ image analysis software
(National Institutes of Health, Bethesda, MD, USA). Total area of the
slices, AAR, and infarct size were measured, and each measurement was
weighted with the weight of each individual slice. The evaluation of
infarct size was performed using images with assigned numbers not
related to the received treatment, and hence blinding the observer.
Fig. 1. Protocol design. Schematic illustration of the study design and ex-
perimental protocol. Grey areas represent periods with occlusion of the left
anterior descending artery (LAD). DMSO, dimethylsulfoxide; IPC, ischemic
preconditioning; XE991, KV7 channel blocker.
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2.9. Statistical analysis
Radiotelemetry MAP and heart rate recordings were evaluated using
a 2-way ANOVA, comparing baseline MAP before each XE991 admin-
istration with the MAP every following 30 min until 2 h. Myograph
results were evaluated by 2-way ANOVA comparing to vehicle-treated
preparations. Action potentials were evaluated using a paired t-test
comparing XE991 traces with vehicle action potentials recorded before
XE991 application. Weight, age, mortality, comparison between AAR,
amount of anesthesia and infarct size in animals subjected to AMI were
evaluated by 1-way ANOVA, followed by Tukey's multiple comparison
post hoc test when appropriate. MAP and heart rate in anesthetized
animals were evaluated from the time of XE991/DMSO administration
and every 30th min±3 min until the end of the experiment by a 1-way
ANOVA with repeated measures followed by Tukey's multiple com-
parison post hoc test. Statistical analysis of the data was performed
using GraphPad Prism (Graphpad Software, La Jolla, CA, version 5.02).
All data are presented as means ± S.E.M. P < 0.05 was considered
statistically significant.
3. Results
3.1. Telemetric blood pressure studies and ECG measurements
In the telemetry studies performed in conscious rats, 0.075 mg/kg
XE991 did not change MAP (Fig. 2A). Administration of 0.75 mg/kg
and 7.5 mg/kg XE991 increased MAP (Fig. 2B and C), while the heart
rate was only significantly different from vehicle-treated animals after
the administration of the highest dose of XE991 (Fig. 2D–F). Six rats
were treated with vehicle, and nine rats were treated with XE991. Four
out of nine rats (44%) died 2.2 h ± 0.4 h after injection of 7.5 mg/kg
XE991.
Compared to vehicle, XE991 induced marked changes in the ECG
(Fig. 3A–F). XE991 increased P wave amplitude and duration, increased
the PR interval, prolonged the QTC, and increased the T amplitude at
0.075 and 0.75 mg/kg, while the T wave was reversed at the high dose
of 7.5 mg/kg of XE991 (Table 1). A pronounced change induced by
XE991 in the ECG was reduction in the amplitude of the QRS complex
(Fig. 3 D-F, Supplementary Table 1).
Fig. 2. Mean arterial blood pressure (MAP) and heart rate in conscious rats.MAP after administration of, respectively, (A) 0.075 mg/kg, (B) 0.75 mg/kg and (C)
7.5 mg/kg of XE991. Heart rate after administration of, respectively, (D) 0.075 mg/kg, (E) 0.75 mg/kg and (F) 7.5 mg/kg of XE991. MAP and heart rate are presented
every 30 min ±4 min, the baseline is 12 min ±4 min before each XE991 administration. n = 6–9. *P < 0.05 versus vehicle.
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In contrast to animals administered vehicle, 50% of the anesthetized
rats injected with XE991 developed myoclonus ranging from small
twitches in the lower limbs, jaw muscles and abdominal skin to shaking
of the head. Generalized myoclonus was observed in two out of eight
animals administered 7.5 mg/kg XE991 (see also supplementary video).
In summary, these results show that XE991 increases blood pressure
induced marked changes in ECG, and in high doses is associated with
skeletal muscle contractions in intact animals.
Supplementary video related to this article can be found at https://
doi.org/10.1016/j.ejphar.2019.172820.
3.2. Effect of XE991 on small rat mesenteric arteries
Added at baseline tension, XE991 (10−7-10−4 M) failed to induce
contraction. In arteries contracted with phenylephrine to 20% of their
maximum response, XE991 concentration-dependently increased vas-
cular tone compared to vehicle (Fig. 4A). In arteries contracted with the
thromboxane analog, U46619 (10−7 M), the β-adrenoceptor agonist
isoprenaline, induced concentration-dependent relaxations that were
inhibited in the presence of XE991 (10−5 M) (Fig. 4B). In summary,
XE991 increases contraction and inhibits vasorelaxation in resistance
arteries, and this may explain the increase in blood pressure.
3.3. Effect of XE991 on rat cardiac action potentials
In the intact rats, there were marked changes in the ECG. In intact
atrial preparations in vitro, incubation with XE991 (10−5 M) failed to
change the membrane potential (Fig. 5A), and the duration of action
potential at the level of 90% repolarization was unchanged (Fig. 5B).
XE991 (10−5 M) tended to slow spontaneous beating rate of right atrial
preparations by 3.3 ± 1.5%, but this effect was not significant. As a
control, the same experiment was conducted in hearts from guinea-pigs,
and in these atrial preparations, XE991 prolonged the action potentials
(Supplementary Fig. S1). The cardiac IKs channel is a macromolecular
complex composed of a pore-forming α (KCNQ1 or KV7.1) subunit and
modulatory β (KCNE1) subunit, as well as intercellular proteins (Osteen
et al., 2010). Our findings suggest that there is no direct effect of XE991
on cardiomyocytes of intact rats, unlike the myocytes of species, e.g.
guinea-pigs with profound cardiac IKs current.
3.4. Hemodynamic effects of IPC and KV7 channel blockade
In the anesthetized rats, the age, weight and amount of anesthesia
did not differ among the four experimental groups subjected to AMI.
Several rats were excluded from the study due to development of ar-
rhythmia or heart failure and hypotension (Table 2). MAP was sig-
nificantly higher in the two experimental groups receiving XE991
compared to the vehicle (Fig. 6A). The MAP in the XE991 group was
slightly but statistically lower than in the XE991 + IPC group. In all
four groups, the blood pressure was reduced over time (Fig. 6A). The
heart rate was significantly lower in the IPC group compared to the
vehicle (Fig. 6B), but there was no statistical difference between the
vehicle and any other group. In agreement with the observations in
conscious animals, XE991 increases blood pressure, while IPC decreases
heart rate in rats subjected to ischemia-reperfusion injury.
3.5. Effect of IPC and KV7 channel blockade on infarct size
We monitored the oxygen saturation throughout the protocol, and
in all experimental groups, the mean saturation was held stable above
97% from the beginning of the protocol until the LAD occlusion, and it
was considered sufficient for normal tissue function (data not shown).
The AAR was calculated based on the infusion of Evans blue, and
there was no significant difference of the AAR normalized to the total
weight of the heart in the four groups (data not shown). In the vehicle-
treated rats, the myocardial infarcts were apparent and at gross ex-
amination larger than in the rats given IPC, suggesting a cardiopro-
tective effect of the procedure (Fig. 7A–D). Indeed, infarct size/AAR
was reduced from 53 ± 2% in the vehicle group (n = 8) to 36 ± 3%
in the IPC group (n = 9). Similarly, infarct size/AAR was significantly
Fig. 3. Original traces showing the effect of vehicle and XE991 on electrocardiographic recordings (lead II) in the rat heart. (A–C) Effect on the ECG 2 and
30 min after injection of vehicle. (D–F) Effect on the ECG 2 and 30 min after injection of XE991 (D) 0.075 mg/kg, (E) 0.75 mg/kg, and (F) 7.5 mg/kg. Please see
Table 1 for the quantitative data.
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reduced to 36 ± 3% in the group receiving both XE991 and IPC
(n = 9), and there was no difference between the IPC and XE991 + IPC
group (Fig. 7E). Treatment with only the KV7 channel blocker XE991
failed to reduce infarct size/AAR (48 ± 5%, n = 9) compared to the
vehicle (Fig. 7E). Infarct size was plotted against MAP, and across the
four experimental groups, we did not observe a direct relation of infarct
size to MAP (Fig. 7F). In summary, there is effect of IPC on myocardial
infarct size, while there is no effect of XE991.
4. Discussion
Recently, we found that IPC and the KV7 channel blocker XE991 are
cardioprotective in isolated rat hearts (Hedegaard et al., 2016). To
avoid pronounced increases in MAP, myoclonus, and death, we chose to
administer 0.75 mg/kg XE991, which increased MAP and caused ECG
changes but failed to protect the heart against ischemia-reperfusion
injury. In contrast, we found that IPC also exerts cardioprotective effect
in intact rats.
4.1. Hemodynamic effects of IPC and XE991





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 4. Effect of XE991 in small rat mesenteric arteries on contraction and
relaxation. (A) Rat mesenteric arteries contracted with phenylephrine to 20%
of the maximum contraction, and cumulative concentration-response curves
were constructed for of XE991 and equal amounts of the vehicle (without
XE991). (B) Preparations contracted with the thromboxane analog U46619
(10−7 M). Concentration-dependent relaxations induced by isoprenaline were
inhibited in the presence of 10−5 M XE991. Data are means ± S.E.M. n = 6.
*P < 0.05.
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was no response to administration of 0.075 mg/kg XE991, but marked
MAP increases with higher doses of XE991 Administration of 0.75 mg/
kg XE991 in anesthetized rats, independent of IPC, also increased MAP.
The heart rate did not differ between the vehicle and the XE991-treated
groups suggesting that XE991 increases peripheral resistance. Indeed,
XE991 induces vasoconstriction in murine isolated arteries and LAD
(Yeung et al., 2007; Hedegaard et al., 2016; Khanamiri et al., 2013),
and human mesenteric arteries (Ng et al., 2011). In the present study,
XE991 in isolated rat mesenteric arteries increased contractions in-
duced by the α-adrenoceptor agonist, phenylephrine, and inhibited
relaxations induced by the β-adrenoceptor agonist, isoprenaline. These
findings support vasoconstriction underlies the increase in MAP caused
by XE991.
The mixture of ketamine and xylazine is known to reduce cardiac
output and blood pressure compared to other anesthetics (Plante et al.,
2006; Shekarforoush et al., 2016; Stein et al., 2007) because xylazine
activates central α2-adrenoceptors and reduces sympathetic nerve ac-
tivity and thereby blood pressure. In the present study, the baseline
MAP was also lower in the anesthetized compared to the conscious
animals, and MAP decreased over time in all four experimental groups.
Several animals developed heart failure due to infarcted myocardium
and impaired heart function after ischemia-reperfusion (Table 2), and
this is also reflected in the overall decrease in MAP. However, there was
no relation of infarct size to MAP across the four experimental groups.
We chose the mixture of S-ketamine and xylazine for the anesthesia to
avoid the volatile anesthetics, since they exert cardioprotective effects
themselves (Ludwig et al., 2003; Tsutsumi et al., 2006), and opioids
protect the heart against ischemia-reperfusion injury and abolish the
cardioprotective effect of IPC (Schultz et al., 1995, 1996; Gross et al.,
2004). Furthermore, ketamine and xylazine reduce ventricular fi-
brillation compared to pentobarbital anesthesia, which may be im-
portant since malignant arrhythmias are common in the AMI rat model
(Shekarforoush et al., 2016; Opitz et al., 1995). Indeed, in our study,
only two rats died of malignant arrhythmia.
Some studies have found a significantly lower heart rate in the IPC
group before 45-min occlusion, and at the end of the reperfusion period
Fig. 5. Action potential in intact rat right
atrium preparations. (A) Original action po-
tential traces in one representative preparation
in control conditions and after 7 min of perfu-
sion with 10−5 M XE991. (B) Mean action po-
tential duration (APD) at 90% repolarization
level in control and the presence of XE991. Data
are means ± S.E.M. n = 5. *P < 0.05 versus
vehicle action potentials recorded prior to
XE991 application.
Table 2
Animal characteristics and exclusions in the acute myocardial infarction study.
Group Number of animals Body weight Reason for exclusion Mortality rate Included
Malignant arrhythmia Hypotension, heart failure
Vehicle 14 315 ± 32 g 6 43% 8
IPC 17 321 ± 35 g 2 6 47% 9
XE991 16 313 ± 28 g 7 44% 9
XE991 + IPC 17 319 ± 33 g 8 47% 9
Total 64 2 27 35
Weights are means ± S.E.M. Malignant arrhythmia was verified by sudden loss of MAP and missing heart rate as well as visually assessed lack of regular heart
function.
Fig. 6. Mean arterial blood pressure (MAP)
and heart rate in anesthetized rats with
acute myocardial infarction (AMI). (A) MAP
in the four experimental groups during and after
the AMI procedure. MAP is presented every
30 min ±3 min after XE991 or DMSO admin-
istration and until the end of the experiment. (B)
Heart rate of the four groups during and after
the AMI procedure. Heart rate is presented every
30 min ± 3 min after XE991 or vehicle admin-
istration and until the end of the experiment.
*P < 0.05 versus vehicle. n = 7–9. bpm, beats
per min.
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(Matsumura et al., 2000; Gourine et al., 2005), although this is not a
consistent finding. We also observed that the IPC group had a lower
heart rate than the other experimental groups. In previous studies in
isolated hearts, coronary arteries, and isolated cardiomyocytes, hypoxia
was found to increase KV7 channel activation, an effect blocked by
XE991 (Khanamiri et al., 2013; Hedegaard et al., 2014). In the present
study, the decrease in heart rate in the rats exposed to IPC was abol-
ished in the presence of XE991. These findings suggest an involvement
of KV7 channels in the reduction of heart rate in rats exposed to IPC,
although further studies will be required to elucidate the significance of
these findings.
4.2. Effect of IPC and XE991 on infarct size
IPC was reported to protect the human heart against ischemic injury
and to reduce adverse cardiac events following heart surgery (Davies
et al., 2013; Heusch and Rassaf, 2016). However, other studies do not
find better clinical outcome for patients subjected to IPC (Walsh et al.,
2016; Hausenloy et al., 2015). Although many animal models do not
take into account age and disease-related changes such as athero-
sclerosis, diabetes, and hypertension, there is abundant evidence
showing IPC induces a reduction in infarct size in ischemia-reperfusion
studies in animals (Murry et al., 1986; Piot et al., 1997). In the present
study, ischemia was induced for 40 min followed by reperfusion similar
to our previous studies in isolated rat hearts (Hedegaard et al., 2016),
and also used in intact animal studies by others (Lai et al., 2015; Macchi
et al., 2014; Kalakech et al., 2014). The infarct size of 50% of the AAR
induced in the intact animals in the present study is similar to that
reported by others (Wojciechowska et al., 2013; Uryash et al., 2012;
Cheng et al., 2010). Moreover, in the present study IPC significantly
reduced infarct size, supporting that it has a cardioprotective effect.
We found that blockade of KV7 channels with XE991 protected the
isolated rat heart against ischemia-reperfusion injury and that com-
bining IPC and XE991 had an additive protective effect (Hedegaard
et al., 2016). In contrast, the systemic administration of XE991 failed to
protect the heart against reperfusion injury in the present study, and
there was no additive effect of treatment with XE991 in rats undergoing
IPC before the ischemia-reperfusion. Other studies have found cardio-
protective effects of pharmacological agents in isolated, Langendorff
perfused hearts, but not in clinical trials (Wang et al., 2007; Roolvink
et al., 2016; Lee et al., 2017; Roos et al., 2016). In previous studies on
isolated hearts, XE991 (10 μM) was administered directly in circulating
buffer before the occlusion and for the rest of the experiment
(Hedegaard et al., 2016). In the present study, XE991 was administered
systemically, allowing less control of the precise concentration of
XE991 in the heart, but an estimated concentration of 1 μM XE991.
XE991 (0.6–0.8 μM) blocks the KV7.1, KV7.2, and heterotetramers of
KV7.2 and KV7.3 channels, while the sensitivity of KV7.4 is 3–5 μM
(Wang et al., 1998; Sogaard et al., 2001), and of KV7.5 60–65 μM to
XE991 (Schroeder et al., 2000). Thus, in the isolated heart studies,
XE991 will block the KV7.1–7.4 channels while there will be much less
effect on the KV7.4 channel in the present study in the intact animals.
KV7.4 channels in the rat cardiac mitochondria have been suggested to
contribute to cardioprotection (Testai et al., 2016), and we may spec-
ulate that selective modulation of this channel may confer cardiopro-
tection also in intact animals. However, the present findings suggest
that the highest dose of XE991, that we can administer without con-
siderable mortality and which has direct effect on the heart and car-
diovascular system, fails to protect the heart after ischemia-reperfusion
in intact animals.
Large increases in afterload were found to cause larger infarcts and
to worsen recovery of mechanical function after ischemia-reperfusion
(Mozaffari et al., 2006). An increase in MAP leading to increased
afterload may counteract the cardioprotective effects of XE991. To
address this issue, we plotted infarct size against MAP in the recovery
period. There was no relation of the blood pressure and infarct size in
the present study, suggesting that an increase in afterload did not
counteract a cardioprotective effect of XE991. This is also supported by
the observation that in animals exposed to IPC and XE991, IPC still had
an cardioprotective impact despite an increase in MAP.
The dominant KV7 channels in the brain are KV7.2, KV7.3, and
KV7.5, while KV7.4 is rarely detected (Barrese et al., 2018). The KV7
channel opener, retigabine, is an anticonvulsant (Main et al., 2000),
and tremor and impaired movements have previously been observed in
Fig. 7. Effect of ischemic preconditioning
(IPC) and XE991 on myocardial infarct size.
Transverse slices of hearts after staining with
Evans blue and TTC (2,3,5-triphenyltetrazolium
chloride), examples from the experimental
groups: vehicle (A), IPC (B), XE991 (C) and
XE991 + IPC (D). Pale areas were infarcted, red
areas were at risk for infarction, and the dark
areas were well-perfused withblood. (E) Average
effect of Kv7 blockade (0.75 mg/kg XE991) and
IPC on myocardial infarct size (IS). (F)
Normalized infarct size (IS/AAR) plotted against
meanarterial blood pressure (MAP). There was
no relation. *P < 0.05 versus vehicle. n = 8–9.
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rats given the KV7 blocker XE991 orally (0.625 mg/kg) (Zaczek et al.,
1998). We found myoclonus in 50% of the rats treated with XE991, and
after administration of the high dose of XE991 (7.5 mg/kg), 44% of the
rats died. Our findings of lack of effect of XE991 in the intact myo-
cardial preparations also support that the effect of XE991 has central
autonomic origin, rather than a direct effect on the myocardium in
intact rats. These observations prevented us from meaningful testing of
higher dose of XE991 (7.5 mg/kg) on ischemia-reperfusion. Given there
is no cardioprotective effects of a lower dose of XE991, other ap-
proaches including chemical modification of XE991 to avoid central
effects or selective modulation of KV7.4 channels, will be required to
clarify whether cardioprotection in intact animals is feasible by tar-
geting KV7 channels.
5. Conclusion and perspective
The main findings of the present study are that IPC exerts cardio-
protective effects in rats in vivo, and despite XE991 had cardiovascular
effects reflected by increased MAP in both anesthetized and conscious
animals, systemic administration of XE991 failed to protect the heart
against ischemia-reperfusion injury. This contrasts with our previous
studies showing that XE991 is cardioprotective in the isolated rat heart
(Hedegaard et al., 2016). It would be a perspective to optimize and aim
for testing drugs targeting the KV7 channel subtypes in the heart, and to
avoid that it affects the KV7 channels in the brain and increases the
afterload by activation of KV7 channels in the vasculature.
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